Clinical Trial

Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction

Completed Phase 2/3
View on ClinicalTrials.gov →
Summary
Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.Erectile dysfunction (ED) is one of the commonest disorders in adult males and affects 12-19% of men of reproductive age.Erectile dysfunction can be due to vasculogenic, neurogenic, hormonal, veno-occlusive, psychogenic and/or pharmacogenic factors. PRP is autologous plasma that has a platelet concentration above the concentrations typically found in whole blood and is derived from the patient's own blood (autologous) through a process of centrifugation. PDE5Is inhibit the enzyme phosphodiesterase-5 (PDE-5) leading to dilatation of the penile arteries leads to a more prolonged erection.
Trial Details
NCT Number NCT07761806
Lead Sponsor Ain Shams University
Conditions Erectile Dysfunction
Enrollment 75 participants
Start Date 2024-01-15
Primary Completion 2024-08-25 (estimated)
Study Completion 2024-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12